Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers are provided for domestic and international callers and the access code 166837 applies. A live webcast will be available via the company's Events/Investor Relations pages and will be archived for later viewing. Participants are recommended to connect at least 15 minutes before the scheduled start to ensure a timely connection.
Positive
- None.
Negative
- None.
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
| Conference Call & Webcast | |
| Thursday, November 6 at 4:30 p.m. ET | |
| Domestic: | 1 833-470-1428 |
| International: | 1 646-844-6383 |
| Access Code: | 166837 |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) report Q3 2025 results?
What time is the CRNX conference call and webcast for Q3 2025?
How can investors join the CRNX Q3 2025 conference call?
Where can I watch the Crinetics (CRNX) Q3 2025 webcast?
Will the CRNX Q3 2025 webcast be available after the call?
Any tips for connecting to the Crinetics Q3 2025 call on November 6?
